Akanda

Akanda operates a world-leading EU GMP-certified cultivation facility in Portugal, distributing premium medical cannabis to fast-growing markets in Europe. The company boasts the only commercial-scale premium indoor EU GMP certified and licensed grow in Portugal, with an annual production exceeding 2,000kg. Akanda is building a seed-to-patient supply chain, connecting patients in the UK and Europe with diverse cannabis products, and manufactures high-quality medical cannabis and wellness products. The company provides cannabis-based medicine to international patients through leading prescribing doctors, digital pain clinics, and distribution partners. Akanda has a genetics and retail partnership with Cookies, one of the world’s top cannabis brands, and owns Holigen, which includes a high-quality 20,000 square foot indoor facility near Lisbon and a large seven million square foot outdoor facility in Aljustrel, Portugal. Holigen’s facilities allow for the production of two tonnes of premium indoor cannabis and over 100 tonnes of outdoor cannabis annually. Akanda cooperates with Cansativa GmbH to supply the German market with dried flowers from its EU-GMP certified indoor grow facility in Sintra, Portugal. CanMart Ltd., a wholly owned subsidiary, is a fully licensed UK importer and wholesaler of medical cannabis. The company partners with Cellen’s Leva Clinic, the first fully online clinic for patients with chronic pain partnered with the NHS and Boots. The European cannabis market is projected to reach $3.8 billion by 2025. Akanda became a public company on March 15, 2022, and is incorporated as a public limited company in Canada without physical operations there. The fiscal year ends on December 31, and the independent auditor is BF Borgers CPA PC. Akanda’s common stock is publicly traded on the Nasdaq Capital Market under the ticker symbol ‘AKAN’, with Continental Stock Transfer & Trust Company as the transfer agent. The company has created the Akanda Bokamoso Empowerment Trust to provide workers with a direct stake worth approximately 3% of the issued share capital.